Mubadala Bio’s IDS Signs Exclusive Distribution Agreement with L-Nutra to Expand Access to Longevity-Focused Nutrition Solutions in the UAE

Mubadala Bio today announced the signing of an exclusive distribution and promotional agreement with L-Nutra, a global leader in longevity nutrition during Make it in the Emirates 2026, the UAE’s flagship industrial platform taking place at ADNEC Centre Abu Dhabi.  The agreement will be executed through Al Ittihad Drug Store (IDS), a company within its Pharma Logistics vertical.

The agreement was signed by Hamad Almarzooqi, Group Deputy CEO, Mubadala Bio and Joseph Antoun, CEO, L Nutra and witnessed by Ismail Ali Abdulla, Head of UAE Clusters at Mubadala’s UAE Investments Platform. Under the partnership, Mubadala Bio will exclusively market and distribute L-Nutra’s longevity nutrition products through Al Ittihad Drug Store (IDS) across the UAE, including ProLon, L-Nutra’s Fast Mimicking Diet products.

The partnership adds a new dimension to Mubadala Bio’s expanding portfolio, broadening access to longevity products to consumers in the UAE, while advancing its broader vision to strengthen the life sciences sector through modern, unique healthcare products.

L-Nutra has been expanding its presence in the region. Earlier this year, Mubadala Investment Company announced a strategic investment in L-Nutra, alongside the establishment of a joint venture in Abu Dhabi focused on producing longevity-focused nutrition for the Middle East and North Africa, reinforcing the UAE’s position as a hub for advanced life sciences and preventative healthcare.

Ismail Ali Abdulla, Head of UAE Clusters at Mubadala’s UAE Investments Platform said: “This partnership represents a natural progression of our investment in L-Nutra and reflects Abu Dhabi’s ambition to advance as a regional hub for life sciences. By expanding access to L-Nutra’s products in the UAE, we are delivering innovative solutions to individuals in a more efficient and accessible way.”

Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, said: “This partnership reflects Mubadala Bio’s ambition to lead in areas that are shaping the future of life sciences. Working with L-Nutra allows us to expand access to longevity nutrition solutions across the UAE, reinforcing our role as a trusted partner in delivering better health, closer for all.”

Dr. Joseph Antoun, CEO of L-Nutra, said: “We are pleased to partner with Mubadala Bio’s IDS to expand access to our products across the UAE. This agreement supports our broader growth plans and we look forward to working closely together to be able to provide our longevity nutrition products to more people.”

Al Ittihad Drug Store (IDS), part of Mubadala Bio’s Pharma Logistics vertical, is one of the UAE’s leading distributors and a trusted partner for a broad portfolio of pharmaceutical and consumer products. Earlier this year, Mubadala Bio completed the full acquisition of IDS, further strengthening its logistics capabilities. With a nationwide distribution network reaching healthcare providers, pharmacies and supermarkets across the UAE, IDS plays a key role in ensuring the reliable and efficient availability of healthcare products, supported by strong operational expertise and a continued focus on advancing access to care.

Mubadala Bio Acquires Full Ownership of IDS and GMSC

Mubadala Bio, a life sciences company committed to advancing better health outcomes for the UAE and beyond, announced that it has finalized the full acquisition of Al Ittihad Drug Store (IDS) and Global Medical Supply Chain (GMSC) from Yas Holding’s GlobalOne Healthcare Holding, following the initial 80% acquisition at the end of 2024.

The completion of this transaction reflects Mubadala Bio’s continued progress in building a vertically integrated life sciences platform in the UAE. By bringing together biopharmaceutical manufacturing and pharmaceutical logistics under a unified strategy, the company is reinforcing its commitment to strengthening the national life sciences ecosystem.

Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio said: “This strategic move supports Mubadala Bio’s vertical integration strategy, creating greater efficiency and stronger coordination across the life sciences value chain. It also reinforces national drug security by ensuring essential healthcare products are consistently available across the UAE.”

Low Ping, Group CEO of Yas Holding, commented: “We are pleased to confirm Mubadala Bio’s full ownership and control of IDS and GMSC.  The proven capability and reach of both companies will help ensure resilience and efficiency not just across Mubadala Bio’s growing life sciences platform, but also our national healthcare supply chain”.

Through full ownership of IDS and GMSC, Mubadala Bio advances its mission to strengthen national drug security, reinforce critical pharmaceutical distribution networks, and help build a robust, integrated life sciences ecosystem that supports the UAE’s ambition for a resilient, innovation-driven healthcare sector.

Read more here